The AP reports that “Eli Lilly said Thursday its COVID-19 antibody drug can prevent illness in residents and staff of nursing homes and other long-term care locations” in “the first major study to show such a treatment may prevent disease.” In a study of over 1,000 participants, recipients of “the drug had up to a 57% lower risk of getting COVID-19 compared to others at the same facility who got a placebo, the drugmaker said,” with the risk “reduced by up to 80%” among residents only. Lilly “said it would publish results in a journal soon,” and, “said it will seek expansion” of its FDA emergency use authorization “to include using the drug to prevent and treat COVID-19 in long-term care facilities.”
The Wall Street Journal reports that Lilly Chief Scientific Officer Daniel Skovronsky said the antibody treatment, bamlanivimab, may be useful as a preventive measure before vaccines reach long-term care facilities, which account for a major percentage of COVID-related deaths. According to the CDC, about 1.9 million doses have been administered to nursing homes, which house approximately 3 million residents. The New York Times reports, “The data have not yet been peer-reviewed or published,” though “the company expects to present the findings at a future medical meeting and to publish them in a peer-reviewed journal.”
From the news release of the American Association for Justice.

